ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1997

Histologic and Clinical Correlates of Ultrasound Measures of Joint Inflammation: Analysis of RA Tissue Obtained by Ultrasound Guided Biopsy in Phase 2 of the Accelerating Medicines Partnership RA Network

Diane Horowitz1, Andrew Filer 2, Jennifer Albrecht 3, Arthur Mandelin 4, Darren Tabechian 5, Edward DiCarlo 6, Brendan Boyce 3, Ellen Gravallese 7, Peter Gregersen 8, Dagmar Scheel-Toellner 9, Kevin Wei 10, Katherine Liao 11, Larry Moreland 12, V. Michael Holers 13, Michael Brenner 14, Jennifer Anolik 3 and Vivian Bykerk 15, 1Northwell Health, Great Neck, NY, 2Institute of Inflammation and Ageing College of Medical and Dental Sciences University of Birmingham, Birmingham, United Kingdom, 3University of Rochester Medical Center, Rochester, NY, 4Northwestern University Feinberg School of Medicine, Division of Rheumatology, Chicago, IL, 5University of Rochester, Rochester, NY, 6Hospital for Special Surgery, New York, 7University of Massachusetts Medical School, Worcester, MA, 8Feinstein Institutes for Medical Research, Manhasset, NY, 9University of Birmingham, Birmingham, United Kingdom, 10Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 11Brigham and Women's Hospital, Boston, 12University of Pittsburgh, PITTSBURGH, PA, 13University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Denver, 14Brigham and Women’s Hospital:, Boston, 15Hospital for Special Surgery, New York City, NY

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Early Rheumatoid Arthritis, Synovial Immune Biology and ultrasound

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: RA – Etiology & Pathogenesis Poster II

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: The AMP-RA network applies cutting edge molecular single cell technologies to study synovial tissue obtained from rheumatoid arthritis (RA) patients using US guided synovial biopsy (USGSB). Ultrasound can provide objective joint level measures of synovial inflammation, including hypertrophy (greyscale ultrasound, GSUS) and hyperemia (Power Doppler ultrasound, PDUS). Phase 1 AMP-RA demonstrated that USGSB was effective and safe for obtaining synovial tissue in the United States in patients with RA. In Phase 2 RA patients with active disease were recruited based on treatment exposure. We examined the relationship between joint level US variables, clinical characteristics, and synovial histology in Phase 2 patients.

Methods: In this multi-center study, eligible AMP-RA Phase 2 subjects had classifiable RA, ≥2 actively inflamed joints including the biopsied “sentinel” joint, a CDAI >10, and a GSUS of ≥2 of the biopsied joint.  Biopsies were done using either QuickCore™ needle or Portal and Forceps. Subject Groups defined by treatment exposure were: (1) DMARD naïve/ minimally exposed ( ≤ 4 weeks of MTX)( (n=40), (2) MTX-IR despite ≥3 months of MTX (n=29), (3) TNF-IR despite ≥3 months of anti-TNF therapy. US scanned sentinel joints were scored using a 4-point semi-quantitative scale of GSUS and PDUS alongside composite RA disease activity measures. Retrieved tissue was fixed, stained and paraffin embedded, then sectioned and stained by H&E. Tissues were assessed for quality based on presence of and quantity of lining layer and synovium. Tissues were scored using 2 of 3 Krenn domains: lining layer (Krenn L)(0-3) and inflammatory infiltrate (Krenn I)(0-3) by three pathologists (BB, ED, EG).

Results: Of 119 synovial biopsies obtained from 13 sites across the USA and UK, 93 (83%) were of good quality. Clinical Groups 1, 2, and 3 had similar disease activity and US scores but the expected differences in disease duration (Table 1).  GSUS, PDUS, CDAI, and Disease Duration were similar between the samples regardless of histology quality. Krenn scores differed between the Groups: Group 1 biopsies had higher mean Krenn(I) and Krenn(L) scores and a greater proportion with Krenn(L) and Krenn(I) scores of >1 (Table 2). PDUS grade correlated with the Krenn(L) and the Krenn(I) scores (p=0.003, r=0.32). GSUS grade failed to correlate with either histological measure (p=0.55, p=0.43 respectively).

Conclusion: In this cohort, the clinical and ultrasound characteristics did not correlate with tissue quality.  Ultrasound measures of synovial hyperemia correlate with histologic joint infiltrates.  Group 1 subjects had the shortest disease duration and least medication exposure.  Despite such, Group 1 had higher mean Krenn(I) scores when compared to the MTX-IR (Group 2) and TNF-IR (Group 3) subjects.


Table1-DH

Table 1: Clinical, Ultrasound and Histology correlates for 3 clinical groups.


Table2

Table 2: Krenn scores for 3 Clinical Groups


Disclosure: D. Horowitz, None; A. Filer, None; J. Albrecht, None; A. Mandelin, None; D. Tabechian, None; E. DiCarlo, None; B. Boyce, None; E. Gravallese, None; P. Gregersen, None; D. Scheel-Toellner, None; K. Wei, None; K. Liao, None; L. Moreland, None; V. Holers, AdMIRx, 1, 2, 4, 5, 6, Alexion, 7, BMS, 5, Bristol-Myers Squibb, 5, Celgene, 5, Janssen R&D, 2, 5, Pfizer, 2; M. Brenner, None; J. Anolik, None; V. Bykerk, AbbVie, 5, Amgen, 1, 2, 3, 5, 8, Brainstorm Therapeutics, 1, 2, 3, 5, 8, Bristol-Myers Squibb, 5, Genentech, 5, Gilead, 5, NIH, 2, Pfizer, 1, 2, 3, 5, 8, Regeneron, 5, Regeneron Pharmaceuticals, Inc, 5, Sanofi, 5, Sanofi/Genzyme-Regeneron, 5, Sanofi-Genzyme/Regeneron, 1, 2, 3, 5, 8, Scipher, 1, 2, 3, 5, 8, The Cedar Hill Foundation, 9, UCB, 1, 2, 3, 5, 8, UCB Pharma, 5.

To cite this abstract in AMA style:

Horowitz D, Filer A, Albrecht J, Mandelin A, Tabechian D, DiCarlo E, Boyce B, Gravallese E, Gregersen P, Scheel-Toellner D, Wei K, Liao K, Moreland L, Holers V, Brenner M, Anolik J, Bykerk V. Histologic and Clinical Correlates of Ultrasound Measures of Joint Inflammation: Analysis of RA Tissue Obtained by Ultrasound Guided Biopsy in Phase 2 of the Accelerating Medicines Partnership RA Network [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/histologic-and-clinical-correlates-of-ultrasound-measures-of-joint-inflammation-analysis-of-ra-tissue-obtained-by-ultrasound-guided-biopsy-in-phase-2-of-the-accelerating-medicines-partnership-ra-netw/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/histologic-and-clinical-correlates-of-ultrasound-measures-of-joint-inflammation-analysis-of-ra-tissue-obtained-by-ultrasound-guided-biopsy-in-phase-2-of-the-accelerating-medicines-partnership-ra-netw/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology